Home・Akciju saraksts・Pacira Pharmaceuticals Inc-DE

Pacira Pharmaceuticals Inc-DE

Slēgts

SektorsVeselības aprūpe

27.59 3.41

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

26.19

Max

27.59

Galvenie mērījumi
By Trading Economics
Ienākumi	1.3M 2.9M
Pārdošana	-19M 177M
P/E Sektora vidējais	207.077 68.51
EPS	0.6
Peļņas marža	1.644
Darbinieki	825
EBITDA	5M 30M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+17.64% upside

Dividendes
By Acuity
Nākamie ieņēmumi	2026. g. 5. nov.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-40M 1.1B
Iepriekšējā atvēršanas cena	24.18
Iepriekšējā slēgšanas cena	27.59

Ziņu noskaņojums

By Acuity

50%

175 / 340 Rangs Healthcare

Pacira Pharmaceuticals Inc-DE Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 4. aug. 19:53 UTC

Pacira Biosciences Inc is higher today, supported by overall market strength and a decline in crude oil prices easing inflation concerns.

2026. g. 3. aug. 20:06 UTC

Pacira Biosciences Inc. shares are higher today, reflecting broader market gains led by major stocks, despite no specific company news identified.

2026. g. 31. jūl. 20:02 UTC

Pacira Biosciences Inc's shares are lower today, reaching a session low earlier. The price remains above its 20-day moving average despite the decline.

2026. g. 30. jūl. 17:16 UTC

Pacira Biosciences is advancing during Thursday's session, regaining momentum after earlier pulling back from a session high amid broader market optimism.

2026. g. 29. jūl. 20:04 UTC

Shares of Pacira Biosciences Inc. are lower today, continuing a decline since Tuesday's close. The stock reached an early high before falling significantly.

2026. g. 28. jūl. 19:56 UTC

Event

News

Shares of Pacira Biosciences Inc. are higher, driven by survey findings on orthopedic pain's impact on the workforce and strong interest in non-opioid treatments.

2026. g. 27. jūl. 18:51 UTC

Event

News

Pacira Biosciences advances PCRX-201 to commercial manufacturing, allowing patient enrollment in Phase 2 ASCEND study. Shares are higher as investor confidence strengthens.

2026. g. 24. jūl. 17:16 UTC

Pacira Biosciences Inc shares are lower today, with no specific news driving the decline. Broader market sentiment is impacted by falling crude oil prices.

2026. g. 22. jūl. 18:06 UTC

Pacira Biosciences Inc shares are lower in Wednesday's session, pulling back from earlier gains amid broader market caution and rising crude oil prices.

2026. g. 21. jūl. 19:56 UTC

Pacira Biosciences Inc is trading higher, reflecting broader market interest in technology and AI sectors ahead of upcoming earnings reports.

2026. g. 20. jūl. 19:46 UTC

Pacira Biosciences Inc shares are trading lower today, having retraced from an earlier high. No specific news was identified to explain the decline.

Salīdzinājums

Cenas izmaiņa

Pacira Pharmaceuticals Inc-DE Prognoze

Cenas mērķis

By TipRanks

17.64% augšup

Prognoze 12 mēnešiem

Vidējais 31.67 USD 17.64%

Augstākais 38 USD

Zemākais 25 USD

Pamatojoties uz 3 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Pacira Pharmaceuticals Inc-DE — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

3 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 3 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Pacira Pharmaceuticals Inc-DE — pēdējo 3 mēnešu laikā.

Noskaņojums

By Acuity

175 / 340 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Pacira Pharmaceuticals Inc-DE

Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.